Literature DB >> 35231809

The impact of head and neck radiotherapy on salivary flow and quality of life: Results of the ORARAD study.

Alexander Lin1, Erika S Helgeson2, Nathaniel S Treister3, Brian L Schmidt4, Lauren L Patton5, Linda S Elting6, Rajesh V Lalla7, Michael T Brennan8, Thomas P Sollecito9.   

Abstract

OBJECTIVES: Salivary hypofunction and xerostomia, are common side effects of radiotherapy, negatively impacting quality of life. The OraRad study presents results on the longitudinal impact of radiotherapy on salivary flow and patient-reported outcomes. PATIENTS AND METHODS: Prospective, multicenter cohort study of 572 patients receiving curative-intent head and neck radiotherapy (RT). Stimulated salivary flow (SSF) rate and patient-reported outcomes were measured prior to RT and at 6- and 18-months post-RT. Linear mixed effects models examined the relationship between RT dose and change in salivary flow, and change in patient-reported outcomes.
RESULTS: 544 patients had baseline salivary flow measurement, with median (IQR) stimulated flow rate of 0.975 (0.648, 1.417) g/min. Average RT dose to parotid glands was associated with change in salivary flow post-RT (p < 0.001). Diminished flow to 37% of pre-RT level was observed at 6 months (median: 0.358, IQR: 0.188 to 0.640 g/min, n = 481) with partial recovery to 59% of pre-RT at 18 months (median: 0.575, IQR: 0.338 to 0.884 g/min, n = 422). Significant improvement in patient-reported swallowing, senses (taste and smell), mouth opening, dry mouth, and sticky saliva (p-values < 0.03) were observed between 6 and 18 months post-RT. Changes in swallowing, mouth opening, dry mouth, and sticky saliva were significantly associated with changes in salivary flow from baseline (p-values < 0.04).
CONCLUSION: Salivary flow and patient-reported outcomes decreased as a result of RT, but demonstrated partial recovery during follow-up. Continued efforts are needed to improve post-RT salivary function to support quality of life.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Head and Neck Neoplasms; Quality of Life; Radiotherapy; Xerostomia

Mesh:

Year:  2022        PMID: 35231809      PMCID: PMC8977268          DOI: 10.1016/j.oraloncology.2022.105783

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  26 in total

1.  Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study.

Authors:  Brian O'Sullivan; Shao Hui Huang; Jie Su; Adam S Garden; Erich M Sturgis; Kristina Dahlstrom; Nancy Lee; Nadeem Riaz; Xin Pei; Shlomo A Koyfman; David Adelstein; Brian B Burkey; Jeppe Friborg; Claus A Kristensen; Anita B Gothelf; Frank Hoebers; Bernd Kremer; Ernst-Jan Speel; Daniel W Bowles; David Raben; Sana D Karam; Eugene Yu; Wei Xu
Journal:  Lancet Oncol       Date:  2016-02-27       Impact factor: 41.316

2.  Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.

Authors:  Bhishamjit S Chera; Robert J Amdur; Joel E Tepper; Xianming Tan; Jared Weiss; Juneko E Grilley-Olson; D Neil Hayes; Adam Zanation; Trevor G Hackman; Samip Patel; Nathan Sheets; Mark C Weissler; William M Mendenhall
Journal:  Cancer       Date:  2018-03-26       Impact factor: 6.860

3.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States.

Authors:  Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

4.  Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.

Authors:  Bhishamjit S Chera; Robert J Amdur; Rebecca Green; Colette Shen; Gaorav Gupta; Xianming Tan; Mary Knowles; David Fried; Neil Hayes; Jared Weiss; Juneko Grilley-Olson; Shetal Patel; Adam Zanation; Trevor Hackman; Jose Zevallos; Jeffrey Blumberg; Samip Patel; Mohit Kasibhatla; Nathan Sheets; Mark Weissler; Wendell Yarbrough; William Mendenhall
Journal:  J Clin Oncol       Date:  2019-08-14       Impact factor: 44.544

5.  Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial.

Authors:  Anthony C Nichols; Julie Theurer; Eitan Prisman; Nancy Read; Eric Berthelet; Eric Tran; Kevin Fung; John R de Almeida; Andrew Bayley; David P Goldstein; Michael Hier; Khalil Sultanem; Keith Richardson; Alex Mlynarek; Suren Krishnan; Hien Le; John Yoo; S Danielle MacNeil; Eric Winquist; J Alex Hammond; Varagur Venkatesan; Sara Kuruvilla; Andrew Warner; Sylvia Mitchell; Jeff Chen; Martin Corsten; Stephanie Johnson-Obaseki; Libni Eapen; Michael Odell; Christina Parker; Bret Wehrli; Keith Kwan; David A Palma
Journal:  Lancet Oncol       Date:  2019-08-12       Impact factor: 41.316

6.  Combination of submandibular salivary gland transfer and intensity-modulated radiotherapy to reduce dryness of mouth (xerostomia) in patients with head and neck cancer.

Authors:  Rufus A Scrimger; Hadi Seikaly; Larissa J Vos; Jeffrey Harris; Dan O'Connell; Sunita Ghosh; Brock Debenham; Naresh Jha
Journal:  Head Neck       Date:  2018-09-03       Impact factor: 3.147

7.  Defining high-risk elective contralateral neck radiation volumes for oropharynx cancer.

Authors:  Matthew E Witek; Neil M Woody; Hima B Musunuru; Patrick M Hill; Poonam Yadav; Adam R Burr; Huaising C Ko; Richard B Ross; Randall J Kimple; Paul M Harari
Journal:  Head Neck       Date:  2021-11-11       Impact factor: 3.147

8.  Patients with head and neck cancer cured by radiation therapy: a survey of the dry mouth syndrome in long-term survivors.

Authors:  Oda B Wijers; Peter C Levendag; Mirjam M J Braaksma; Meindert Boonzaaijer; Leo L Visch; Paul I M Schmitz
Journal:  Head Neck       Date:  2002-08       Impact factor: 3.147

9.  Influence of parotid-sparing radiotherapy on xerostomia in head and neck cancer patients.

Authors:  J Gabriel Malouf; Cecilia Aragon; Brad S Henson; Avraham Eisbruch; Jonathan A Ship
Journal:  Cancer Detect Prev       Date:  2003

10.  Localized Delivery of Amifostine Enhances Salivary Gland Radioprotection.

Authors:  J J Varghese; I L Schmale; D Mickelsen; M E Hansen; S D Newlands; D S W Benoit; V A Korshunov; C E Ovitt
Journal:  J Dent Res       Date:  2018-04-10       Impact factor: 6.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.